orphan drug status
In Brief This Week: A2 Biotherapeutics, Ellipses Pharma, Quanterix, Verismo Therapeutics
News items for the week of March 4, 2024.
Precision Oncology Drugmakers Are the IRA's Staunchest Adversaries—And They're Not Backing Down
Premium
Medicare price negotiations officially began this week, but drugmakers are determined to challenge the law's constitutionality in front of the highest court.
Gracell Biotechnologies Begins Treating B-NHL Patients With CAR T-Cell Therapy in Trial
The firm believes that targeting both CD19 and BCMA with its investigational GC012F CAR T-cell therapy will benefit patients more than cell therapies with a single target.
The University of Modena and Reggio Emilia spinoff is awaiting word from European regulators so it can start the first human trial of its autologous MSC-based gene therapy.
Prestige Biopharma to Begin Anti-PAUF Drug Trial for Pancreatic Cancer in France
French regulators have permitted the start of a Phase I/II clinical trial of PBP1510 in pancreatic cancer patients whose tumors overexpress PAUF.